A Phase I/II, Multi-Center, Open Label Study of DYP688 in Patients with Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas
Clinical Trials
Preoperative immune-therapy combination shows promise in skin cancer
Treatment with the drugs relatlimab and nivolumab before the surgical removal of a type of cancer called melanoma resulted in tumours becoming inviable in 57% of individuals, and no severe adverse effects were observed.
Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in a Phase II study, researchers from The University of Texas MD Anderson Cancer Center reported in Nature today.
IMC-F106C Shows Potential as T-cell Receptor–Driven Therapy in Melanoma
Results from a first-in-humanphase 1 trial (NCT04262466) evaluating the efficacy and safety of IMC-F106C in patients with PRAME-positive metastatic/unresectable tumors showed a significant clinical benefit with the first PRAME×CD3 ImmTAC therapy, and could specifically fulfill unmet needs for patients with melanoma, according to Omid Hamid, MD.